NYU School of Medicine, New York, NY
Anne Olsen , Deanna Gerber , Olivia R Khouri , Jessica Lee , Julia Fehniger , Bhavana Pothuri
Background: The NCCN recommends risk-reducing salpingo-oophorectomy (RRSO) for women with BRCA mutations by age 35-40 or upon completion of childbearing. We previously reported that RRSO was being performed at age 43-44; and age 46-47 when fertility considerations were excluded. Since these ages are past the NCCN guidelines, our objective was to elucidate the timing between genetic testing (GT) and risk-reducing surgery (RRS) and reasons for delay. Methods: We conducted a retrospective chart review to identify women with BRCA mutations who underwent RRSO between 2012-2017. We analyzed demographics, date of GT and RRS and reasons for delay in RRS. Results: We identified 187 patients with mutations who underwent RRS: 93 with BRCA1 and 94 with BRCA2. Median age at RRS was 44 (28-77); 43 (31-77) and 45 (28-71), for BRCA1 and BRCA2, respectively. The median time between GT and RRS was 9 (1-171) months (m). Fifty-six percent of patients (n = 105) had a documented reason for delay in RRS: 39 (37%) for future fertility; 25 (24%) for breast cancer (BC) treatment; 14 (13%) due to fear of surgical menopause; 10 (10%) to coordinate with simultaneous breast surgery; 17 (16%) miscellaneous. The median time of delay from mutation diagnosis to RRS among groups was: fertility, 29 (3-171) m; BC, 9 (2-36) m; menopause, 12 (4-76) m; and surgical coordination, 8 (4-13) m. Median age at RRS among groups was: fertility, 39 (31-46) years (y); BC, 45 (28-70) y; menopause, 42 (32-44) y; and surgical coordination, 52 (37-71) y. In patients undergoing RRS after diagnosis of BC, 30 of 36 (83%) had a family history that qualified them for earlier genetic testing by NCCN guidelines. Two of these BC patients had ovarian cancer at the time of RRS. Conclusions: Overall, patients underwent RRS within a year of mutation diagnosis. Patients comprised two distinct groups: those with fertility or menopause concerns who underwent RRS at 39-42 y, close to the NCCN recommended age; and those with BC who underwent RRS at 45-52 y. Over 80% of patients in the BC group qualified for earlier genetic screening. Obtaining a family history, referral for GT, and earlier diagnosis of mutations, prior to development of BC, will be an important step to better comply with NCCN guidelines and prevent ovarian cancer.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: June Evelyn Jeon
2023 ASCO Annual Meeting
First Author: Rebecca A. Previs
2022 ASCO Annual Meeting
First Author: Ana Teresa Pina
2023 ASCO Annual Meeting
First Author: Muneer V. A.